We are especially interested in supporting fellowships focused on:
- New target validation, including in animal models and human cell models.
- Target or pathway biology in disease-relevant models, including defining upstream/downstream modifiers and convergence of promising target pathways.
- Factors that could ultimately reduce the risk of developing ALS, including studies of genetic risk factors, epigenetics, gene-environment interactions, lifestyle, occupational or dietary factors and epidemiology.
- New biomarker identification and the development and/or validation of biomarker assays.
- Managing ALS, including the development and/or validation of novel assistive technology and measurement of patient/caregiver/family burden.
- Analysis of omics data from resources including, but not limited to, PRO-ACT, Project MinE or Answer ALS to identify disease-relevant patient subtypes, new therapeutic targets or new biomarkers.
• Individuals who received their terminal research degree (i.e., Ph.D.) and/or reached the end of postgraduate clinical training less than 2 years before the date letters of intent are due (i.e., on or after November 21, 2021) are eligible to apply.
• Applicants must have the skills, knowledge, and resources necessary to carry out the proposed research and have an existing postdoctoral position, including the support of their mentor.
$150,000 in total funding over 2 years to support the development of junior postdoctoral fellows who received their terminal research degree (i.e., Ph.D.) and/or reached the end of postgraduate clinical training less than 2 years before the date letters of intent are due